1. Home
  2. NAN vs ALT Comparison

NAN vs ALT Comparison

Compare NAN & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAN
  • ALT
  • Stock Information
  • Founded
  • NAN 1999
  • ALT 1997
  • Country
  • NAN United States
  • ALT United States
  • Employees
  • NAN N/A
  • ALT N/A
  • Industry
  • NAN Investment Managers
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • NAN Finance
  • ALT Health Care
  • Exchange
  • NAN Nasdaq
  • ALT Nasdaq
  • Market Cap
  • NAN 342.0M
  • ALT 292.0M
  • IPO Year
  • NAN N/A
  • ALT N/A
  • Fundamental
  • Price
  • NAN $10.97
  • ALT $3.83
  • Analyst Decision
  • NAN
  • ALT Strong Buy
  • Analyst Count
  • NAN 0
  • ALT 6
  • Target Price
  • NAN N/A
  • ALT $17.40
  • AVG Volume (30 Days)
  • NAN 74.6K
  • ALT 3.0M
  • Earning Date
  • NAN 01-01-0001
  • ALT 08-12-2025
  • Dividend Yield
  • NAN 4.37%
  • ALT N/A
  • EPS Growth
  • NAN N/A
  • ALT N/A
  • EPS
  • NAN N/A
  • ALT N/A
  • Revenue
  • NAN N/A
  • ALT $20,000.00
  • Revenue This Year
  • NAN N/A
  • ALT N/A
  • Revenue Next Year
  • NAN N/A
  • ALT $761,880.20
  • P/E Ratio
  • NAN N/A
  • ALT N/A
  • Revenue Growth
  • NAN N/A
  • ALT N/A
  • 52 Week Low
  • NAN $9.11
  • ALT $2.90
  • 52 Week High
  • NAN $11.34
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • NAN 37.01
  • ALT 51.79
  • Support Level
  • NAN $10.89
  • ALT $3.35
  • Resistance Level
  • NAN $10.94
  • ALT $3.66
  • Average True Range (ATR)
  • NAN 0.06
  • ALT 0.19
  • MACD
  • NAN -0.00
  • ALT 0.07
  • Stochastic Oscillator
  • NAN 33.33
  • ALT 86.18

About NAN Nuveen New York Quality Municipal Income Fund

Nuveen New York Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal, New York State and New York City income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: